

(DANRE) adra2db Blocking Peptide (C-Term)
Synthetic peptide
Catalog # BP21170a

Specification

(DANRE) adra2db Blocking Peptide (C-Term) - Product Information

Primary Accession [Q8JG69](#)

(DANRE) adra2db Blocking Peptide (C-Term) - Additional Information

Gene ID 266755

Other Names

Alpha-2Db adrenergic receptor, Alpha-2Db adrenoceptor, Alpha(2Db)AR, Alpha-2Db adrenoreceptor, adra2db

Target/Specificity

The synthetic peptide sequence is selected from aa 323-336 of HUMAN adra2db

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

(DANRE) adra2db Blocking Peptide (C-Term) - Protein Information

Name adra2db

Function

Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The order of potency for this receptor is dexmedetomidine > norepinephrine = epinephrine > oxymetazoline.

Cellular Location

Cell membrane; Multi-pass membrane protein.

(DANRE) adra2db Blocking Peptide (C-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

(DANRE) adra2db Blocking Peptide (C-Term) - Images**(DANRE) adra2db Blocking Peptide (C-Term) - Background**

Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The order of potency for this receptor is dexmedetomidine > norepinephrine = epinephrine > oxymetazoline.

(DANRE) adra2db Blocking Peptide (C-Term) - References

Ruuskanen J.O.,et al.Mol. Biol. Evol. 21:14-28(2004).
Ruuskanen J.O.,et al.Br. J. Pharmacol. 144:165-177(2005).